Jump to content

Thalassemia

From Wikipedia, the free encyclopedia
(Redirected from Thalassemia Major)

Thalassemia
Other namesThalassaemia, Mediterranean anemia
Peripheral blood film from a person with delta-beta thalassemia
Pronunciation
SpecialtyHematology
SymptomsFeeling tired, pale skin, enlarged spleen, yellowish skin, dark urine[1]
CausesGenetic (autosomal recessive)[2]
Diagnostic methodBlood tests, genetic tests[3]
TreatmentBlood transfusions, iron chelation, folic acid[4]
Frequency280 million (2015)[5]
Deaths16,800 (2015)[6]

Thalassemias are inherited blood disorders that manifest as the production of reduced or zero quantities of hemoglobin.[7] Symptoms depend on the type of thalassemia and can vary from none to severe, including death.[1] Often there is mild to severe anemia (low red blood cells or hemoglobin) as thalassemia can affect the production of red blood cells and also affect how long the red blood cells live.[1] Symptoms of anemia include feeling tired and having pale skin.[1] Other symptoms of thalassemia include bone problems, an enlarged spleen, yellowish skin, pulmonary hypertension, and dark urine.[1] Slow growth may occur in children.[1] Clinically, thalassemia is classed as Transfusion-Dependent Thalassemia (TDT) or non-Transfusion-Dependent Thalassemia (NTDT), since this determines the principal treatment options. TDT requires regular transfusions, typically every two to five weeks. TDTs include Beta-thalassemia major, nondeletional HbH disease, survived Hb Bart's disease, and severe HbE/beta-thalassemia. NTDT does not need regular transfusions but may require transfusion in case of an anemia crisis.[8]

Thalassemias are genetic disorders.[2] There are two main types, alpha thalassemia and beta thalassemia.[7] The severity of alpha and beta thalassemia depends on how many of the four genes for alpha globin or two genes for beta globin are missing.[2] Diagnosis is typically by blood tests including a complete blood count, special hemoglobin tests, and genetic tests.[3] Diagnosis may occur before birth through prenatal testing.[9]

Treatment depends on the type and severity.[4] Treatment for those with more severe disease often includes regular blood transfusions, iron chelation, and folic acid.[4] Iron chelation may be done with deferoxamine, deferasirox or deferiprone.[4][10] Occasionally, a bone marrow transplant may be an option.[4] Complications may include iron overload from the transfusions with resulting heart or liver disease, infections, and osteoporosis.[1] If the spleen becomes overly enlarged, surgical removal may be required.[1] Those people who do not respond well to blood transfusions can take hydroxyurea or thalidomide, and sometimes a combination of both.[11] Hydroxyurea is the only FDA approved drug for thalassemia. Taking 10 mg/kg of hydroxyurea every day for a year significantly increased hemoglobin levels, and it was well-tolerated treatment for those who did not respond well to blood transfusions.[12] Other known hemoglobin-inducers include thalidomide, but it has not been tested in a clinical setting. The combination of thalidomide and hydroxyurea resulted in hemoglobin levels increasing significantly in transfusion-dependent and non-transfusion dependent patients [13]

As of 2015, thalassemia occurs in about 280 million people, with about 439,000 having severe disease.[14] It is most common among people of Greek, Italian, Middle Eastern, South Asian, and African descent.[7] Males and females have similar rates of disease.[citation needed] It resulted in 16,800 deaths in 2015, down from 36,000 deaths in 1990.[6][15] Those who have minor degrees of thalassemia, in common with those who have sickle-cell trait, have some protection against malaria, explaining why sickle-cell trait and thalassemia are more common in regions of the world where the risk of malaria is higher.[16] An estimated 1/3 of people with thalassemia have "non-transfusion dependent thalassemia" and do not depend on regularly continuing blood transfusions to survive.

Signs and symptoms

[edit]
Left: Hand of a person with severe anemia. Right: Hand of a person without anemia.
A patient having thalassemia shows enlarged spleen.
  • Iron overload: People with thalassemia can get an overload of iron in their bodies, either from the disease itself or from frequent blood transfusions. Too much iron can result in damage to the heart, liver, and endocrine system, which includes glands that produce hormones that regulate processes throughout the body. The damage is characterized by excessive deposits of iron. Without adequate iron chelation therapy, almost all patients with beta-thalassemia accumulate potentially fatal iron levels.[17]
  • Infection: People with thalassemia have an increased risk of infection. This is especially true if the spleen has been removed.[18]
  • Bone deformities: Thalassemia can make the bone marrow expand, which causes bones to widen. This can result in abnormal bone structure, especially in the face and skull. Bone marrow expansion also makes bones thin and brittle, increasing the risk of broken bones.[19]
  • Enlarged spleen: The spleen aids in fighting infection and filters unwanted material, such as old or damaged blood cells. Thalassemia is often accompanied by the destruction of a large number of red blood cells and the task of removing these cells causes the spleen to enlarge. Splenomegaly can make anemia worse, and it can reduce the life of transfused red blood cells. Severe enlargement of the spleen may necessitate its removal.[20]
  • Slowed growth rates: anemia can cause the growth of a child to slow down. Puberty may also be delayed in children with thalassemia.[21]
  • Heart problems: Diseases, such as congestive heart failure and abnormal heart rhythms, may be associated with severe thalassemia.[22]

Hemoglobin structural biology

[edit]
(a) schematic representation of a hemoglobin molecule, showing alpha and beta globins. (b) structure of the heme molecular component of hemoglobin

Normal human hemoglobins are tetrameric proteins composed of two pairs of globin chains, each of which contains one alpha-like (α-like) chain and one beta-like (β-like) chain. Each globin chain is associated with an iron-containing heme moiety. Throughout life, the synthesis of the alpha-like and the beta-like (also called non-alpha-like) chains is balanced so that their ratio is relatively constant and there is no excess of either type.[23]

The specific alpha and beta-like chains that are incorporated into Hb are highly regulated during development:

  • Embryonic Hbs are expressed as early as four to six weeks of embryogenesis and disappear around the eighth week of gestation as they are replaced by fetal Hb.[24][25] Embryonic Hbs include:
    • Hb Gower-1, composed of two ζ globins (zeta globins) and two ε globins (epsilon globins) (ζ2ε2)
    • Hb Gower-2, composed of two alpha globins and two epsilon globins (α2ε2)
    • Hb Portland I, composed of two zeta globins and two gamma globins (ζ2γ2)
    • Hb Portland II, composed of two zeta globins and two beta globins (ζ2β2)
  • Fetal Hb (Hb F) is produced from approximately eight weeks of gestation through birth and constitutes approximately 80 percent of Hb in the full-term neonate. It declines during the first few months of life and, in the normal state, constitutes <1 percent of total Hb by and past early childhood. Hb F is composed of two alpha globins and two gamma globins (α2γ2). Patients with β-thalassemia exhibit higher levels of gamma globulin, and thus more production of Hb F, to counteract the imbalance from not being able to produce beta chains.[26]
  • Adult Hb (Hb A) is produced at low levels through embryonic and fetal life and is the predominant Hb in children by six months of age and onward; it constitutes 96-97% of total Hb in individuals without a hemoglobinopathy. It is composed of two alpha globins and two beta globins (α2β2).[citation needed]
  • Hb A2 is a minor adult Hb that normally accounts for approximately 2.5-3.5% of total Hb from six months of age onward. It is composed of two alpha globins and two delta globins (α2δ2).[citation needed]

Cause

[edit]
Thalassemia has an autosomal recessive pattern of inheritance.

Both α- and β-thalassemias are often inherited in an autosomal recessive manner. Cases of dominantly inherited α- and β-thalassemias have been reported, the first of which was in an Irish family with two deletions of 4 and 11 bp in exon 3 interrupted by an insertion of 5 bp in the β-globin gene. For the autosomal recessive forms of the disease, both parents must be carriers for a child to be affected. If both parents carry a hemoglobinopathy trait, the risk is 25% for each pregnancy for an affected child.[27]

The genes involved in thalassemia control the production of healthy hemoglobin. Hemoglobin binds oxygen in the lungs and releases it when the red cells reach peripheral tissues, such as the liver. The binding and release of oxygen by hemoglobin are essential for survival.[citation needed]

Evolution

[edit]

Having a single genetic variant for thalassemia may protect against malaria and thus can be an advantage.[28]

People diagnosed with heterozygous (carrier) β-thalassemia have some protection against coronary heart disease.[29]

Pathophysiology

[edit]

Normally, the majority of adult hemoglobin (HbA) is composed of four protein chains, two α and two β-globin chains arranged into a heterotetramer. In thalassemia, patients have defects in the noncoding region of either the α or β-globin genes, causing ineffective production of normal alpha- or beta-globin chains, which can lead to ineffective erythropoiesis, premature red blood cell destruction, and anemia.[30]

The thalassemias are classified according to which chain of the hemoglobin molecule is affected. In α-thalassemias, production of the α-globin chain is affected, while in β-thalassemia, production of the β-globin chain is affected.[31]

The β-globin chains are encoded by a single gene on chromosome 11; α-globin chains are encoded by two closely linked genes on chromosome 16.[32] Thus, in a healthy person with two copies of each chromosome, two loci encode the β chain, and four loci encode the α chain. Deletion of one of the α loci has a high prevalence in people of African or Asian descent, making them more likely to develop α-thalassemia. β-thalassemias are not only common in Africans, but also in Greeks and Turks.[citation needed]

Alpha-thalassemias

[edit]
Main article: Alpha-thalassemia

The α-thalassemias involve the genes HBA1[33] and HBA2,[34] inherited in a Mendelian recessive fashion. Two gene loci and so four alleles exist. Two genetic loci exist for α-globin, thus four alleles are in diploid cells. Two alleles are maternal and two alleles are paternal in origin. The severity of the α-thalassemias is correlated with the number of affected α-globin; alleles: the greater, the more severe will be the manifestations of the disease.[35] Alpha-thalassemias result in decreased alpha-globin production; therefore, fewer alpha-globin chains are produced, resulting in an excess of β chains in adults and excess γ chains in newborns. The excess β chains form unstable tetramers (called hemoglobin H or HbH of 4 beta chains), which have abnormal oxygen dissociation curves. Alpha thalassemias often are found in people from Southeast Asia, the Middle East, China, and in those of African descent.[36]

# of missing alleles Types of alpha thalassemia[35] Symptoms
1 Silent carrier No symptoms
2 Alpha thalassemia trait Minor anemia
3 Hemoglobin H disease Mild to moderate anemia; may lead normal life
4 Hydrops fetalis Death usually occurs in utero or at birth

Beta-thalassemia

[edit]
Main article: Beta-thalassemia

Beta thalassemias are due to mutations in the HBB gene on chromosome 11,[37] also inherited in an autosomal, recessive fashion. The severity of the disease depends on the nature of the mutation and on the presence of mutations in one or both alleles.
Mutated alleles are called β+ when partial function is conserved (either the protein has a reduced function, or it functions normally but is produced in reduced quantity) or βo, when no functioning protein is produced.
The situation of both alleles determines the clinical picture:

  • β thalassemia major (Mediterranean anemia or Cooley anemia) is caused by a βo/βo genotype. No functional β chains are produced, and thus no hemoglobin A can be assembled. This is the most severe form of β-thalassemia;
  • β thalassemia intermedia is caused by a β+/βo or β+/β+ genotype. In this form, some hemoglobin A is produced;
  • β thalassemia minor is caused by a β/βo or β/β+ genotype. Only one of the two β globin alleles contains a mutation, so β chain production is not terribly compromised and patients may be relatively asymptomatic.

Beta thalassemia most often occurs in people of Mediterranean origin. To a lesser extent, Chinese, other Asians, and African Americans can be affected.[36]

Delta-thalassemia

[edit]
Main article: Delta-thalassemia

As well as alpha and beta chains present in hemoglobin, about 3% of adult hemoglobin is made of alpha and delta chains. Just as with beta thalassemia, mutations that affect the ability of this gene to produce delta chains can occur.[38][39]

Combination hemoglobinopathies

[edit]

Thalassemia can coexist with other hemoglobinopathies. The most common of these are:

Diagnosis

[edit]

Thalassemia can be diagnosed via a complete blood count, hemoglobin electrophoresis or high-performance liquid chromatography, and DNA testing.[41][42] Hemoglobin electrophoresis is not widely available in developing countries, but the Mentzer index can also be used for diagnosis of thalassemia; it is not a definitive test but it can suggest the possibility of thalassemia. The Mentzer index can be calculated from a complete blood count report.[43]

Endocrine Complications in Thalassemia

1) Hypogonadism: iron overload in pituitary gonadotropic cells causes decreased gonadotrophin secretion which leads to delayed, slow or arrested puberty.

2) Hypoparathyroidism: chronic anemia causes hematopoiesis which results in bone reabsorption which decreases parathyroid secretion.

3) Adrenal insufficiency: Decreased growth of pubic and axillary hair in adolescent TM patients. This is due to excess iron deposition which causes adrenal dysfunction.

4) Hypothyroidism: Increase in weight and retarded growth in adolescent patients. Secondary is rare and majority suffers from primary hypothyroidism.

[85]

Management

[edit]
Main article: Management of thalassemia

Given the range of severities, some people require no treatment (those who are asymptomatic) while some people require regular blood transfusions for survival.[44] People with severe thalassemia require medical treatment and the main treatment is usually a red blood cell transfusion.

Red blood cell transfusions

[edit]

Blood transfusions are the main treatment approach for prolonging life.[45] The approach and frequency needed varies in each person depending on severity, age, if the person has stunted growth, presence of extramedullary erythropoiesis (pediatrics), if a person is pregnant, and heart health. Blood transfusions come with risks including making iron overload worse, the risk of infections, risk of red blood cell antibody formation, increased risk of the development of hypersensitivity reactions, and the risk of gall bladder inflammation (cholecystitis).[44]

Multiple blood transfusions may result in iron overload. The iron overload related to thalassemia may be treated by chelation therapy with the medications deferoxamine, deferiprone, or deferasirox.[46][47][48] These treatments have resulted in longer life expectancy for those with thalassemia major.[46] Deferoxamine is only effective as a daily injection, complicating its long-term use. However, it is inexpensive and safe. Adverse effects include primary skin reactions around the injection site and hearing loss.[46] Deferasirox and deferiprone are both oral medications, whose common side effects include nausea, vomiting and diarrhea. When comparing effectiveness, there is no evidence that deferasirox or deferiprone is superior, however, a long term comparison has not been performed.[48] Deferasirox is not effective for all patients and may not be suitable for those with significant cardiac issues related to iron overload, while deferiprone appears to be the most effective agent when the heart is involved. Furthermore, the cost of deferasirox is also significant.[46] Combining calcium channel blocker medications with iron chelation therapy is under study, however, the benefits are not clear from clinical trials conducted.[49]

Growth hormone therapy

[edit]

There is some evidence that growth hormone replacement therapy may help to increase the rate at which children with thalassemia grow taller.[50]

Bone-marrow transplantation

[edit]

Bone-marrow transplantation may offer the possibility of a cure in young people who have an HLA-matched donor.[51] Success rates have reached the 80–90% range.[51] Mortality from the procedure is about 3%.[52] There are no randomized controlled trials that have tested the safety and efficacy of non-identical donor bone-marrow transplantation in persons with β- thalassemia who are dependent on blood transfusion.[53]

Graft-versus-host diseases (GvHD) are one relevant side effect of bone-marrow transplantation. Further research is necessary to evaluate whether mesenchymal stromal cells can be used as prophylaxis or treatment for GvHD.[54]

If the person does not have an HLA-matched compatible donor, bone-marrow transplantation from haploidentical mother to child (mismatched donor) may be attempted. In a study of 31 people, the thalassemia-free survival rate was 70%, rejection 23% and mortality 7%. The most positive results tend to occur with very young people.[55]

Gene therapy

[edit]

Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia.[56] It was approved for medical use in the European Union in May 2019,[57] and in the United States in August 2022.[58][59] Betibeglogene autotemcel is indicated for the treatment of people twelve years and older with transfusion-dependent beta thalassemia who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.

The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. The HSCs then have a beta-globin gene added using a lentiviral vector. After destroying the affected person's bone marrow with a dose of chemotherapy (a myeloablative conditioning regimen), the altered HSCs are infused back into the affected person where they become engrafted in the bone marrow where they proliferate. This potentially results in a progressive increase in hemoglobin A2 synthesis in all subsequent developing red blood cells, with resultant resolution of the anemia.[60]

HbF induction

[edit]

Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy for the treatment of transfusion-dependent beta thalassemia. It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.[61]

The treatment was approved in the United Kingdom for the treatment of transfusion-dependent beta thalassemia in November 2023[62][63][64] and in the United States in January 2024.[65][66][67]

Exagamglogene autotemcel is the first cell-based gene therapy treatment utilizing CRISPR/Cas9 gene editing technology to be approved by the US Food and Drug Administration (FDA).[65]

The gene therapy is made from the recipient's own blood stem cells, which are modified, and are given back as a one-time, single-dose infusion as part of a hematopoietic stem cell transplant. Prior to treatment, the recipient's own stem cells are collected, and then the recipient must undergo myeloablative conditioning (high-dose chemotherapy), a process that removes cells from the bone marrow so they can be replaced with the modified cells in exagamglogene autotemcel. The modified blood stem cells are transplanted back into the recipient where they engraft within the bone marrow and increase the production of fetal hemoglobin (HbF), a type of hemoglobin that facilitates oxygen delivery.

Other treatments

[edit]

Hydroxyurea treatment with the goal of reactivating gamma‐genes to produce HbF does not have any high quality evidence supporting its effectiveness.[68]

There is no evidence from randomized controlled trials to support zinc supplementation for those with thalassemia.[69] Computer programs or mobile applications have been suggested as tools to help people manage thalassemia and follow their therapies including iron chelation therapy. The effectiveness of these applications has not been well investigated.[70]

People with thalassemia are at a higher risk of osteoporosis.[71] Treatment options include bisphosphonates and sometimes the addition of hormonal therapy. Other treatments have been suggested including calcitonin, zinc, hydroxyurea, and calcium supplementation. The effectiveness of bisphosphonates and zinc is not clear and further studies are required.[71]

Dental care

[edit]

Helping people with thalassemia with dental care and treating dental problems can be challenging due to the underlying condition. Overload of iron due to blood transfusions may lead to iron deposition in the teeth and discolouration, and there is an increased risk for infection.[72] Treatment options for people with thalassemia need to be modified to ensure that the needs of the person are considered and early detection and early management of any problems is strongly suggested in order to reduce the risk of the person needing more complicated dental treatments.[72] The evidence supporting the effectiveness of dental treatments on people with thalassemia is weak and higher quality clinical trials are needed.[72]

Mild thalassemia

[edit]

People with thalassemia traits do not require medical or follow-up care after the initial diagnosis is made.[45] People with β-thalassemia trait should be warned that their condition can be misdiagnosed as the more common iron-deficiency anemia. They should avoid routine use of iron supplements, but iron deficiency may develop during pregnancy or from chronic bleeding.[73] Genetic counseling is indicated for all persons with genetic disorders, especially when the family is at risk of a severe form of disease that may be prevented.[74]

Prevention

[edit]

The American College of Obstetricians and Gynecologists recommends all people thinking of becoming pregnant be tested to see if they have thalassemia.[75] Genetic counseling and genetic testing are recommended for families who carry a thalassemia trait.[27] Understanding the genetic risk, ideally before a family is started, would hopefully allow families to understand more about the condition and make an informed decision that is best for their family.[27]

A screening policy exists in Cyprus to reduce the rate of thalassemia, which, since the program's implementation in the 1970s (also including prenatal screening and abortion), has reduced the number of children born with the disease from one of every 158 births to almost zero.[76] Greece also has a screening program to identify people who are carriers.[77]

In Iran as a premarital screening, the man's red cell indices are checked first. If he has microcytosis (mean cell hemoglobin < 27 pg or mean red cell volume < 80 fl), the woman is tested. When both are microcytic, their hemoglobin A2 concentrations are measured. If both have a concentration above 3.5% (diagnostic of thalassemia trait) they are referred to the local designated health post for genetic counseling.[78]

Large-scale awareness campaigns are being organized in India[79] both by government and non-government organizations to promote voluntary premarital screening, with marriage between carriers strongly discouraged.

Epidemiology

[edit]

The beta form of thalassemia is particularly prevalent among Mediterranean peoples, and this geographical association is responsible for its original name.[80] Thalassemia resulted in 25,000 deaths in 2013 down from 36,000 deaths in 1990.[15]

In Europe, the highest concentrations of the disease are found in Greece, coastal regions in Turkey (particularly the Aegean Region such as İzmir, Balıkesir, Aydın, Muğla, and Mediterranean Region such as Antalya, Adana, Mersin), in southern Spain, in parts of Italy, particularly southern Italy. With the exception of the Balearics, the major Mediterranean Islands, such as Sicily, Sardinia, Malta, Corsica, Cyprus, and Crete are heavily affected. Other Mediterranean peoples, as well as those in the vicinity of the Mediterranean, also have high rates of thalassemia, including people from North Africa and West Asia. Far from the Mediterranean, South Asians are also affected, with the world's highest concentration of carriers (16–18% of the population) in the Maldives.[81]

The disease is also found in populations living in Africa, the Americas, and in Tharu people in the Terai region of Nepal and India.[82] It is believed to account for much lower rates of malaria illnesses and deaths,[83] accounting for the historic ability of Tharus to survive in areas with heavy malaria infestation while others could not. Thalassemias are particularly associated with people of Mediterranean origin, Arabs (especially Palestinians and people of Palestinian descent), and Asians.[84] The estimated prevalence is 16% in people from Cyprus, 1%[85] in Thailand, and 3–8% in populations from Bangladesh, China, India, Malaysia and Pakistan.

Estimates suggest that approximately 1.5% of the global population (80 – 90 million people) are β-thalassemia carriers.[86] However, exact data on carrier rates in many populations are lacking, particularly in developing areas of the world known or expected to be heavily affected.[87][88] Because of the prevalence of the disease in countries with little knowledge of thalassemia, access to proper treatment and diagnosis can be difficult.[89] While there are some diagnostic and treatment facilities in developing countries, in most cases these are not provided by government services and are available only to patients who can afford them. In general, poorer populations only have access to limited diagnostic facilities and blood transfusions. In some developing countries, there are virtually no facilities for diagnosis or management of thalassemia.[89]

Etymology and synonym

[edit]

The word thalassemia (/θælɪˈsiːmiə/) derives from the Greek thalassa (θάλασσα), "sea",[90] and Neo-Latin -emia (from the Greek compound stem -aimia (-αιμία), from haima (αἷμα), "blood").[91] It was coined because the condition called "Mediterranean anemia" was first described in people of Mediterranean ethnicities. "Mediterranean anemia" was renamed thalassemia major once the genetics were better understood. The word thalassemia was first used in 1932.[80]: 877 [92]

Research

[edit]

References

[edit]
  1. ^ a b c d e f g h "What Are the Signs and Symptoms of Thalassemias?". NHLBI. 3 July 2012. Archived from the original on 16 September 2016. Retrieved 5 September 2016.
  2. ^ a b c "What Causes Thalassemias?". NHLBI. 3 July 2012. Archived from the original on 26 August 2016. Retrieved 5 September 2016.
  3. ^ a b "How Are Thalassemias Diagnosed?". NHLBI. 3 July 2012. Archived from the original on 16 September 2016. Retrieved 5 September 2016.
  4. ^ a b c d e "How Are Thalassemias Treated?". NHLBI. 3 July 2012. Archived from the original on 16 September 2016. Retrieved 5 September 2016.
  5. ^ GBD 2015 Disease and Injury Incidence and Prevalence (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  6. ^ a b GBD 2015 Mortality and Causes of Death (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  7. ^ a b c "What is Thalassemia?". National Heart, Lung, and Blood Institute (NHLBI). 31 May 2022. Retrieved 9 December 2024.{{cite web}}: CS1 maint: url-status (link)
  8. ^ Baird, Drew C.; Batten, Stuart H.; Sparks, Steven K. (1 March 2022). "Alpha- and Beta-thalassemia: Rapid Evidence Review". American Family Physician. 105 (3): 272–280. ISSN 1532-0650. PMID 35289581.
  9. ^ "How Can Thalassemias Be Prevented?". NHLBI. 3 July 2012. Archived from the original on 16 September 2016. Retrieved 5 September 2016.
  10. ^ "Iron Chelation". Retrieved 15 July 2020.
  11. ^ Shah, Sandip; Sheth, Radhika; Shah, Kamlesh; Patel, Kinnari (February 2020). "Safety and effectiveness of thalidomide and hydroxyurea combination in β-thalassaemia intermedia and major: a retrospective pilot study". British Journal of Haematology. 188 (3): e18–e21. doi:10.1111/bjh.16272. ISSN 0007-1048. PMID 31710694. S2CID 207940189.
  12. ^ Keikhaei, Bijan (2015). "Clinical and Haematological Effects of Hydroxyurea in β -Thalassemia Intermedia Patients". Journal of Clinical and Diagnostic Research. 9 (10): OM01-3. doi:10.7860/JCDR/2015/14807.6660. PMC 4625280. PMID 26557561.
  13. ^ Masera, Nicoletta; Tavecchia, Luisa; Capra, Marietta; Cazzaniga, Giovanni; Vimercati, Chiara; Pozzi, Lorena; Biondi, Andrea; Masera, Giuseppe (2010). "Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy". Blood Transfusion. 8 (1): 63–5. doi:10.2450/2009.0102-09. ISSN 1723-2007. PMC 2809513. PMID 20104280.
  14. ^ Global Burden of Disease Study 2013 (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 386 (9995): 743–800. doi:10.1016/s0140-6736(15)60692-4. PMC 4561509. PMID 26063472.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  15. ^ a b GBD 2013 Mortality and Causes of Death (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". The Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. hdl:11655/15525. PMC 4340604. PMID 25530442.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  16. ^ Weatherall, D. J. (2015). "The Thalassemias: Disorders of Globin Synthesis". Williams Hematology (9th ed.). McGraw Hill Professional. p. 725. ISBN 9780071833011.
  17. ^ Cianciulli P (October 2008). "Treatment of iron overload in thalassemia". Pediatr Endocrinol Rev. 6 (Suppl 1): 208–13. PMID 19337180.
  18. ^ "Thalassemia – Symptoms and causes". Mayo Clinic. Archived from the original on 20 November 2016. Retrieved 4 April 2017.
  19. ^ Vogiatzi, Maria G; Macklin, Eric A; Fung, Ellen B; Cheung, Angela M; Vichinsky, Elliot; Olivieri, Nancy; Kirby, Melanie; Kwiatkowski, Janet L; Cunningham, Melody; Holm, Ingrid A; Lane, Joseph; Schneider, Robert; Fleisher, Martin; Grady, Robert W; Peterson, Charles C; Giardina, Patricia J (March 2009). "Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem". Journal of Bone and Mineral Research. 24 (3): 543–557. doi:10.1359/jbmr.080505. ISSN 0884-0431. PMC 3276604. PMID 18505376.
  20. ^ "Symptoms and causes – Enlarged spleen (splenomegaly) – Mayo Clinic". www.mayoclinic.org. Archived from the original on 19 November 2016. Retrieved 2 February 2017.
  21. ^ Soliman, Ashraf T; Kalra, Sanjay; De Sanctis, Vincenzo (1 November 2014). "Anemia and growth". Indian Journal of Endocrinology and Metabolism. 18 (7): S1–5. doi:10.4103/2230-8210.145038. PMC 4266864. PMID 25538873.
  22. ^ "Thalassemia Complications". Thalassemia. Open Publishing. Archived from the original on 3 October 2011. Retrieved 27 September 2011.
  23. ^ Weatherall DJ. The New Genetics and Clinical Practice, Oxford University Press, Oxford 1991.
  24. ^ Huisman TH. The structure and function of normal and abnormal haemoglobins. In: Baillière's Clinical Haematology, Higgs DR, Weatherall DJ (Eds), W.B. Saunders, London 1993. p.1.
  25. ^ Natarajan K, Townes TM, Kutlar A. Disorders of hemoglobin structure: sickle cell anemia and related abnormalities. In: Williams Hematology, 8th ed, Kaushansky K, Lichtman MA, Beutler E, et al. (Eds), McGraw-Hill, 2010. p.ch.48.
  26. ^ Wai Feng Lim, Logeswaran Muniandi, Elizabeth George, Jameela Sathar, Lai Kuan Teh & Mei I Lai (2015) HbF in HbE/β-thalassemia: A clinical and laboratory correlation, Hematology, 20:6, 349-353, DOI: 10.1179/1607845414Y.0000000203
  27. ^ a b c Hussein, Norita; Henneman, Lidewij; Kai, Joe; Qureshi, Nadeem (11 October 2021). Cochrane Cystic Fibrosis and Genetic Disorders Group (ed.). "Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease". Cochrane Database of Systematic Reviews. 2021 (10): CD010849. doi:10.1002/14651858.CD010849.pub4. PMC 8504980. PMID 34634131.
  28. ^ Wambua S; Mwangi, Tabitha W.; Kortok, Moses; Uyoga, Sophie M.; Macharia, Alex W.; Mwacharo, Jedidah K.; Weatherall, David J.; Snow, Robert W.; Marsh, Kevin; Williams, Thomas N. (May 2006). "The Effect of α +-Thalassaemia on the Incidence of Malaria and Other Diseases in Children Living on the Coast of Kenya". PLOS Medicine. 3 (5): e158. doi:10.1371/journal.pmed.0030158. PMC 1435778. PMID 16605300.
  29. ^ Tassiopoulos S; Deftereos, Spyros; Konstantopoulos, Kostas; Farmakis, Dimitris; Tsironi, Maria; Kyriakidis, Michalis; Aessopos, Athanassios (2005). "Does heterozygous beta-thalassemia confer a protection against coronary artery disease?". Annals of the New York Academy of Sciences. 1054 (1): 467–70. Bibcode:2005NYASA1054..467T. doi:10.1196/annals.1345.068. PMID 16339699. S2CID 71993591.
  30. ^ Baird DC, Batten SH, Sparks SK. Alpha- and Beta-thalassemia: Rapid Evidence Review. Am Fam Physician. 2022 Mar 1;105(3):272-280. PMID 35289581.
  31. ^ Herbert l. Muncie, Jr; Campbell, James S. (15 August 2009). "Alpha and Beta Thalassemia". American Family Physician. 80 (4): 339–344. PMID 19678601.
  32. ^ Robbins Basic Pathology, Page No:428
  33. ^ Online Mendelian Inheritance in Man (OMIM): Hemoglobin—Alpha locus 1; HBA1 - 141800
  34. ^ Online Mendelian Inheritance in Man (OMIM): Hemoglobin—Alpha locus 2; HBA2 - 141850
  35. ^ a b Galanello, Renzo; Cao, Antonio (5 January 2011). "Alpha-thalassemia". Genetics in Medicine. 13 (2): 83–88. doi:10.1097/GIM.0b013e3181fcb468. ISSN 1098-3600. PMID 21381239.
  36. ^ a b "The Basics of Anemia". WebMD. Retrieved 9 May 2019.
  37. ^ Online Mendelian Inheritance in Man (OMIM): Hemoglobin—Beta Locus; HBB - 141900
  38. ^ "Delta-beta-thalassemia". Orphanet. Retrieved 16 September 2016.
  39. ^ "HBD - hemoglobin subunit delta". Orphanet. Retrieved 17 September 2016.
  40. ^ Torres Lde S (March 2015). "Hemoglobin D-Punjab: origin, distribution and laboratory diagnosis". Revista Brasileira de Hematologia e Hemoterapia. 37 (2): 120–126. doi:10.1016/j.bjhh.2015.02.007. PMC 4382585. PMID 25818823.
  41. ^ "How Are Thalassemias Diagnosed? – NHLBI, NIH". www.nhlbi.nih.gov. Archived from the original on 28 July 2017. Retrieved 6 September 2017.
  42. ^ Keohane, E; Smith, L; Walenga, J (2015). Rodak's Hematology: Clinical Principles and Applications (5 ed.). Elsevier Health Sciences. pp. 467–9. ISBN 978-0-323-23906-6.
  43. ^ Kottke-Marchant, K; Davis, B (2012). Laboratory Hematology Practice (1 ed.). John Wiley & Sons. p. 569. ISBN 978-1-4443-9857-1.
  44. ^ a b Foong, Wai Cheng; Loh, C Khai; Ho, Jacqueline J; Lau, Doris SC (13 January 2023). Cochrane Cystic Fibrosis and Genetic Disorders Group (ed.). "Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias". Cochrane Database of Systematic Reviews. 2023 (1): CD013767. doi:10.1002/14651858.CD013767.pub2. PMC 9837847. PMID 36637054.
  45. ^ a b Pediatric Thalassemia~treatment at eMedicine
  46. ^ a b c d Neufeld, EJ (2010). "Update on Iron Chelators in Thalassemia". Hematology. 2010: 451–5. doi:10.1182/asheducation-2010.1.451. PMID 21239834.
  47. ^ Fisher, Sheila A.; Brunskill, Susan J.; Doree, Carolyn; Chowdhury, Onima; Gooding, Sarah; Roberts, David J. (21 August 2013). "Oral deferiprone for iron chelation in people with thalassaemia". The Cochrane Database of Systematic Reviews (8): CD004839. doi:10.1002/14651858.CD004839.pub3. ISSN 1469-493X. PMID 23966105.
  48. ^ a b Bollig, Claudia; Schell, Lisa K.; Rücker, Gerta; Allert, Roman; Motschall, Edith; Niemeyer, Charlotte M.; Bassler, Dirk; Meerpohl, Joerg J. (15 August 2017). "Deferasirox for managing iron overload in people with thalassaemia". The Cochrane Database of Systematic Reviews. 2017 (8): CD007476. doi:10.1002/14651858.CD007476.pub3. ISSN 1469-493X. PMC 6483623. PMID 28809446.
  49. ^ Sadaf, Alina; Hasan, Babar; Das, Jai K; Colan, Steven; Alvi, Najveen (12 July 2018). Cochrane Cystic Fibrosis and Genetic Disorders Group (ed.). "Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia". Cochrane Database of Systematic Reviews. 2018 (7): CD011626. doi:10.1002/14651858.CD011626.pub2. PMC 6513605. PMID 29998494.
  50. ^ Ngim, CF; Lai, NM; Hong, JY; Tan, SL; Ramadas, A; Muthukumarasamy, P; Thong, MK (28 May 2020). "Growth hormone therapy for people with thalassaemia". The Cochrane Database of Systematic Reviews. 2020 (5): CD012284. doi:10.1002/14651858.CD012284.pub3. PMC 7387677. PMID 32463488.
  51. ^ a b Gaziev, J; Lucarelli, G (June 2011). "Hematopoietic stem cell transplantation for thalassemia". Current Stem Cell Research & Therapy. 6 (2): 162–9. doi:10.2174/157488811795495413. PMID 21190532.
  52. ^ Sabloff, M; Chandy, M; Wang, Z; Logan, BR; Ghavamzadeh, A; Li, CK; Irfan, SM; Bredeson, CN; et al. (2011). "HLA-matched sibling bone marrow transplantation for β-thalassemia major". Blood. 117 (5): 1745–50. doi:10.1182/blood-2010-09-306829. PMC 3056598. PMID 21119108.
  53. ^ Sharma, Akshay; Jagannath, Vanitha A.; Puri, Latika (21 April 2021). "Hematopoietic stem cell transplantation for people with β-thalassaemia". The Cochrane Database of Systematic Reviews. 2021 (4): CD008708. doi:10.1002/14651858.CD008708.pub5. ISSN 1469-493X. PMC 8078520. PMID 33880750.
  54. ^ Fisher, Sheila A; Cutler, Antony; Doree, Carolyn; Brunskill, Susan J; Stanworth, Simon J; Navarrete, Cristina; Girdlestone, John (30 January 2019). Cochrane Haematological Malignancies Group (ed.). "Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition". Cochrane Database of Systematic Reviews. 1 (1): CD009768. doi:10.1002/14651858.CD009768.pub2. PMC 6353308. PMID 30697701.
  55. ^ Sodani, P; Isgrò, A; Gaziev, J; Paciaroni, K; Marziali, M; Simone, MD; Roveda, A; De Angelis, G; et al. (2011). "T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients". Pediatric Reports. 3 (Suppl 2): e13. doi:10.4081/pr.2011.s2.e13. PMC 3206538. PMID 22053275.
  56. ^ Negre, Olivier; Eggimann, Anne-Virginie; Beuzard, Yves; Ribeil, Jean-Antoine; Bourget, Philippe; Borwornpinyo, Suparerk; Hongeng, Suradej; Hacein-Bey, Salima; Cavazzana, Marina; Leboulch, Philippe; Payen, Emmanuel (February 2016). "Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β – Gene". Human Gene Therapy. 27 (2): 148–165. doi:10.1089/hum.2016.007. PMC 4779296. PMID 26886832.
  57. ^ "Zynteglo EPAR". European Medicines Agency (EMA). 25 March 2019. Archived from the original on 16 August 2019. Retrieved 16 August 2019. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  58. ^ "Zynteglo". U.S. Food and Drug Administration. 17 August 2022. Archived from the original on 26 August 2022. Retrieved 26 August 2022.
  59. ^ "FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions". U.S. Food and Drug Administration (FDA) (Press release). 17 August 2022. Archived from the original on 21 August 2022. Retrieved 20 August 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  60. ^ Biffi, A (19 April 2018). "Gene Therapy as a Curative Option for β-Thalassemia". The New England Journal of Medicine. 378 (16): 1551–1552. doi:10.1056/NEJMe1802169. PMID 29669229.
  61. ^ Stein R (31 October 2023). "FDA advisers see no roadblocks for gene-editing treatment for sickle cell disease". NPR. Archived from the original on 4 December 2023. Retrieved 4 December 2023.
  62. ^ "MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 16 November 2023. Archived from the original on 25 November 2023. Retrieved 8 December 2023.
  63. ^ Sheridan C (November 2023). "The world's first CRISPR therapy is approved: who will receive it?". Nature Biotechnology. 42 (1): 3–4. doi:10.1038/d41587-023-00016-6. PMID 37989785. S2CID 265350318. Archived from the original on 4 December 2023. Retrieved 4 December 2023.
  64. ^ "Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia" (Press release). Vertex Pharmaceuticals. 16 November 2023. Archived from the original on 22 November 2023. Retrieved 9 December 2023 – via Business Wire.
  65. ^ a b "FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease". U.S. Food and Drug Administration (FDA). 8 December 2023. Archived from the original on 8 December 2023. Retrieved 8 December 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  66. ^ "Vertex and CRISPR Therapeutics Announce US FDA Approval of Casgevy (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease" (Press release). Vertex Pharmaceuticals. 8 December 2023. Archived from the original on 9 December 2023. Retrieved 9 December 2023 – via Business Wire.
  67. ^ Commissioner, Office of the (16 January 2024). "FDA Roundup: January 16, 2024". FDA. Retrieved 19 January 2024.
  68. ^ Ansari, Saqib H; Lassi, Zohra S; Khowaja, Salima M; Adil, Syed Omair; Shamsi, Tahir S (16 March 2019). Cochrane Cystic Fibrosis and Genetic Disorders Group (ed.). "Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia". Cochrane Database of Systematic Reviews. 3 (3): CD012064. doi:10.1002/14651858.CD012064.pub2. PMC 6421980. PMID 30882896.
  69. ^ Kye Mon Min Swe (2013). "Zinc supplements for treating thalassaemia and sickle cell disease". Cochrane Database of Systematic Reviews. 2013 (6): CD009415. doi:10.1002/14651858.CD009415.pub2. PMC 9964104. PMID 23807756.
  70. ^ Mulimani, Priti; Abas, Adinegara BL; Karanth, Laxminarayan; Colombatti, Raffaella; Kulkarni, Palna (2 August 2019). Cochrane Cystic Fibrosis and Genetic Disorders Group (ed.). "Treatment of dental and orthodontic complications in thalassaemia". Cochrane Database of Systematic Reviews. 8 (8): CD012969. doi:10.1002/14651858.CD012969.pub2. PMC 6699676. PMID 31425614.
  71. ^ a b Bhardwaj, Amit; Swe, Kye Mon Min; Sinha, Nirmal K.; Osunkwo, Ifeyinwa (10 March 2016). "Treatment for osteoporosis in people with ß-thalassaemia". The Cochrane Database of Systematic Reviews. 3: CD010429. doi:10.1002/14651858.CD010429.pub2. ISSN 1469-493X. PMID 26964506.
  72. ^ a b c Mulimani, Priti; Abas, Adinegara BL; Karanth, Laxminarayan; Colombatti, Raffaella; Kulkarni, Palna (2 February 2023). Cochrane Cystic Fibrosis and Genetic Disorders Group (ed.). "Treatment of dental and orthodontic complications in thalassaemia". Cochrane Database of Systematic Reviews. 2023 (2): CD012969. doi:10.1002/14651858.CD012969.pub3. PMC 9893875. PMID 36732291.
  73. ^ Burdick CO; Ntaios, G.; Rathod, D. (March 2009). "Separating thalassemia trait and iron deficiency by simple inspection". Am. J. Clin. Pathol. 131 (3): 444, author reply 445. doi:10.1309/AJCPC09VRAXEASMH. PMID 19228649.
  74. ^ Harrison's Principles of Internal Medicine (17th ed.). McGraw-Hill medical. September 2008. p. 776. ISBN 978-0-07-164114-2.
  75. ^ "Carrier Screening in the Age of Genomic Medicine – ACOG". www.acog.org. Archived from the original on 25 February 2017. Retrieved 24 February 2017.
  76. ^ Leung TN; Lau TK; Chung TKh (April 2005). "Thalassaemia screening in pregnancy". Current Opinion in Obstetrics and Gynecology. 17 (2): 129–34. doi:10.1097/01.gco.0000162180.22984.a3. PMID 15758603. S2CID 41877258.
  77. ^ Loukopoulos, D (October 2011). "Haemoglobinopathies in Greece: prevention programme over the past 35 years". The Indian Journal of Medical Research. 134 (4): 572–6. PMC 3237258. PMID 22089622.
  78. ^ Samavat A, Modell B (November 2004). "Iranian national thalassaemia screening programme". BMJ (Clinical Research Ed.). 329 (7475): 1134–7. doi:10.1136/bmj.329.7475.1134. PMC 527686. PMID 15539666.
  79. ^ Petrou, Mary (1 January 2010). "Screening for beta thalassaemia". Indian Journal of Human Genetics. 16 (1): 1–5. doi:10.4103/0971-6866.64934. PMC 2927788. PMID 20838484.[permanent dead link‍]
  80. ^ a b Greer, John P.; Arber, Daniel A.; Glader, Bertil; List, Alan F.; Means, Jr., Robert T.; Paraskevas, Frixos; Rodgers, George M.; Foerster, John (2013). Wintrobe's Clinical Hematology. Wolters Kluwer, Lippincott Williams & Wilkins Health. ISBN 9781451172683.
  81. ^ Waheed, Fazeela; Fishter, Colleen; Awofeso, AwoNiyi; Stanley, David (July 2016). "Carrier screening for beta-thalassemia in the Maldives: perceptions of parents of affected children who did not take part in screening and its consequences". Journal of Community Genetics. 7 (3): 243–253. doi:10.1007/s12687-016-0273-5. PMC 4960032. PMID 27393346.
  82. ^ Modiano, G.; Morpurgo, G; Terrenato, L; Novelletto, A; Di Rienzo, A; Colombo, B; Purpura, M; Mariani, M; et al. (1991). "Protection against malaria morbidity: Near-fixation of the α-thalassemia gene in a Nepalese population". American Journal of Human Genetics. 48 (2): 390–7. PMC 1683029. PMID 1990845.
  83. ^ Terrenato, L; Shrestha, S; Dixit, KA; Luzzatto, L; Modiano, G; Morpurgo, G; Arese, P (February 1988). "Decreased malaria morbidity in the Tharu people compared to sympatric populations in Nepal". Annals of Tropical Medicine and Parasitology. 82 (1): 1–11. doi:10.1080/00034983.1988.11812202. PMID 3041928.
  84. ^ E. Goljan, Pathology, 2nd ed. Mosby Elsevier, Rapid Review Series.[page needed]
  85. ^ "Thalassemia" (in Thai). Department of Medical Sciences. September 2011. Archived from the original on 25 September 2011.
  86. ^ Galanello, Renzo; Origa, Raffaella (2010). "Beta-thalassemia". Orphanet Journal of Rare Diseases. 5 (1): 11. doi:10.1186/1750-1172-5-11. PMC 2893117. PMID 20492708.
  87. ^ Galanello, Renzo; Origa, Raffaella (2010). "Beta-thalassemia". Orphanet Journal of Rare Diseases. 5 (1): 11. doi:10.1186/1750-1172-5-11. PMC 2893117. PMID 20492708.
  88. ^ Vichinsky, Elliott P. (1 November 2005). "Changing Patterns of Thalassemia Worldwide". Annals of the New York Academy of Sciences. 1054 (1): 18–24. Bibcode:2005NYASA1054...18V. doi:10.1196/annals.1345.003. ISSN 1749-6632. PMID 16339647. S2CID 26329509.
  89. ^ a b Weatherall, David J. (November 2005). "Keynote Address: The Challenge of Thalassemia for the Developing Countries". Annals of the New York Academy of Sciences. 1054 (1): 11–17. Bibcode:2005NYASA1054...11W. doi:10.1196/annals.1345.002. PMID 16339646. S2CID 45770891.
  90. ^ θάλασσα. Liddell, Henry George; Scott, Robert; A Greek–English Lexicon at the Perseus Project.
  91. ^ αἷμα in Liddell and Scott.
  92. ^ Whipple, GH; Bradford, WI (1932). "Racial or Familial Anemia of Children Associated With Fundamental Disturbances of Bone and Pigment Metabolism (Cooley-Von Jaksch)". American Journal of Diseases of Children. 44: 336–365. doi:10.1001/archpedi.1932.01950090074009.
  • 85. https://journals.lww.com/indjem/fulltext/2013/17010/Growth_and_endocrine_disorders_in_thalassemia__The.3.aspx
  • De Sanctis, Vincenzo; Soliman, Ashraf T.1; Elsedfy, Heba2; Skordis, Nicos3; Kattamis, Christos4; Angastiniotis, Michael5; Karimi, Mehran6; Yassin, Mohd Abdel Daem Mohd7; El Awwa, Ahmed1; Stoeva, Iva8; Raiola, Giuseppe9; Galati, Maria Concetta10; Bedair, Elsaid M.11; Fiscina, Bernadette12; El Kholy, Mohamed2 Author Information Indian Journal of Endocrinology and Metabolism 17(1):p 8-18, Jan–Feb 2013. | DOI: 10.4103/2230-8210.107808
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Thalassemia&oldid=1263569160"